Hope Interrupted: Why Even Short Gaps In Rare Disease Treatment Matter More Than We Think

At the ACMG Annual Conference, a patient story from the ARG1-D community offered a powerful reminder of what is truly at stake when treatment continuity is disrupted in rare disease. The session centered on pegzilarginase, a novel enzyme therapy that gave one patient a dramatic improvement in stamina, mobility, and independence during the PEACE clinical trial. But when the study ended unexpectedly following an asset transition, access to treatment was lost for several months. The consequences were profound.

Symptoms rapidly returned, physical function deteriorated, and many of the gains he had achieved were never recovered, even after treatment resumed. His story illustrates a critical truth in rare disease research: Delays that may seem manageable in corporate or regulatory timelines can have life-altering consequences for patients.

For those living with progressive conditions, treatment gaps are not administrative inconveniences; they can mean irreversible decline. This case underscores the urgent need for stronger continuity planning during trial transitions, handoffs, and asset transfers to protect patient progress and preserve hope.